In this context, recent advances in targeted therapies, such as antibody–drug conjugates, selective estrogen receptor degraders, and nanotechnology-based drug delivery systems, have emerged as promising approaches to overcome resistance mechanisms and improve treatment efficacy in hormone receptor-positive, HER2-negative breast cancer. Here, ERBB2 is linked to breast cancer.